Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025
Acquisition adds taletrectinib, a next-generation,.
Nuvation Bio Inc. entered into an Agreement and Plan of Merger to acquire AnHeart Therapeutics Ltd. on March 24, 2024. Nuvation Bio entered into a definitive agreement for Nuvation Bio to acquire.